Cancer survivor — the plain-language one-pager.

What does it mean to be a Colorectal Cancer Survivor?Diagnosis

About 1.5 million people in the US are living after a colorectal cancer (CRC) diagnosis. CRC survivorship has three pillars: structured surveillance for recurrence and metachronous cancers, management of treatment late effects (especially after pelvic radiation, ostomy, or oxaliplatin neuropathy), and aggressive secondary prevention. CRC is one of the most preventable cancers — and survivors have one of the most leveraged opportunities to lower recurrence risk through diet, activity, weight, and aspirin (in selected patients).

• Surveillance schedule (after curative-intent treatment for stage II–III CRC) — H&P + CEA q3-6 months × 2 years, then q6 months × 3 more years; CT chest/abdomen/pelvis annually × 3-5 years; colonoscopy at 1 year, then 3 years, then 5 years (sooner if abnormal). Stage I + low-risk: less intensive but still scheduled.
• Late effects — Oxaliplatin peripheral neuropathy (often persistent); chemotherapy-related cognitive concerns; bowel dysfunction after low anterior resection ("LAR syndrome"); ostomy care; pelvic radiation (sexual, urinary, bowel); fertility concerns; second primary cancers (especially in Lynch syndrome).
• Lynch syndrome screening — Universal tumor MMR/MSI testing now standard. Lynch+ = lifelong intensive surveillance for CRC, endometrial, ovarian, urothelial, gastric, and other cancers; cascade family testing. Don't miss this conversation.
• Modern aspirin role — Daily low-dose aspirin in selected CRC survivors (especially with PIK3CA-mutated tumors, no bleeding contraindication) appears to reduce recurrence and CRC mortality. Discuss with oncology before starting.

Lynch syndrome — the diagnosis that changes a familyKnow your plan

About 1 in 30 CRC patients has Lynch syndrome — an inherited mismatch-repair gene mutation that dramatically raises lifetime risk of colorectal, endometrial, ovarian, gastric, urothelial, and other cancers. Universal tumor MMR/MSI testing is now standard. If you have not been tested, ask. The result changes your surveillance, your relatives' lives, and your future cancer risks.

• Tumor MMR/MSI testing — usually done at diagnosis; ask your oncologist for the result.
• If MMR-deficient or MSI-high — refer for genetic counseling and germline testing.
• Lynch+ surveillance — colonoscopy q1-2 years lifelong; women: TVUS + endometrial biopsy + risk-reducing hysterectomy/BSO discussion; UA + cytology yearly; consider gastric surveillance.
• Cascade family testing — first-degree relatives screened from a young age (sometimes starting at 20-25); ovarian/endometrial cancer prevention discussions for women in the family.
• Daily aspirin — CAPP2 trial showed substantial CRC risk reduction in Lynch carriers; discuss with your team.

Your daily Force FieldLive It

• CEA + clinic visit on schedule; colonoscopy at 1, 4, 9 years (or per your team); imaging on the surveillance plan.
• Confirm tumor MMR/MSI status; pursue germline testing if recommended; cascade screen relatives if Lynch+.
• Healthy weight, 150+ min/week activity, resistance training 2-3x/week — strongest evidence for reduced recurrence in CRC survivors.
• Mediterranean / DASH eating, high fiber, plant-forward, less red and processed meat.
• Limit alcohol; no tobacco.
• Daily aspirin — discuss with oncology if no bleeding contraindication.
• Bowel dysfunction after LAR — pelvic floor PT, dietary modification, antidiarrheals, structured retraining program.
• Ostomy care — dedicated stoma nurse + supplies; troubleshoot leaks early.
• Oxaliplatin neuropathy — duloxetine first-line; gabapentinoids; PT for balance + falls.
• Sexual + fertility counseling after pelvic surgery / radiation; survivorship clinic resources.

Red flags — call nowAction

• Call your clinic the same day for: new chest discomfort with exertion that goes away with rest (stable recurrence concern worth evaluating); a missed dose of antiplatelet or maintenance therapy; medication side effects (muscle aches, bleeding, GI symptoms).
• Bring up at next visit: any change in exercise tolerance, lipid follow-up timing, BP log review, smoking-cessation support, depression screening, sleep concerns.